Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900524 | 0.93 | PLA2G7 (0.43) | PLA2G7MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL9900555 | 0.90 | PLA2G7 (0.47) | PLA2G7AR | |
| SCHEMBL9900595 | 0.88 | TP53 (0.46) | MEN1KMT2ASMN1; SMN2TP53THRB | |
| SCHEMBL9900226 | 0.86 | SLC22A12 (0.41) | PLA2G7MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL9900841 | 0.85 | PLA2G7 (0.48) | PLA2G7AR | |
| SCHEMBL9106421 | 0.85 | PLA2G7 (0.43) | PLA2G7AR | |
| SCHEMBL9900710 | 0.83 | PLA2G7 (0.47) | PLA2G7AR | |
| SCHEMBL9107909 | 0.81 | PLA2G7 (0.46) | PLA2G7AR | |
| SCHEMBL9901506 | 0.81 | PLA2G7 (0.57) | PLA2G7 | |
| SCHEMBL16617329 | 0.78 | CYP1A2 (0.37) | PLA2G7MEN1KMT2ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |